Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis

This study has been completed.

Study NCT00534794 Information provided by Inspire Pharmaceuticals

First Received: September 20, 2007 Last Updated: April 3, 2009 History of Changes

Study Type:	Interventional
Study Design:	Randomized, Double Blind (Subject, Investigator), Parallel Assignment
Condition:	Allergic Conjunctivitis
Interventions:	Drug: Elestat Drug: Pataday

Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Elestat	1 drop each eye for 2 days
Pataday	1 drop each eye for 1 day

Participant Flow: Overall Study

Baseline Characteristics

Reporting Groups

	Description
Elestat	1 drop each eye for 2 days
Pataday	1 drop each eye for 1 day

Baseline Measures

	Elestat	Pataday	Total
Number of Participants [units: participants]	40	39	79
Age [units: years] Mean ± Standard Deviation	41.3 ± 12.18	40.1 ± 13.41	40.7 ± 12.73
Gender [units: participants]
Female	20	27	47
Male	20	12	32

Outcome Measures

1. Primary:

Change in Ocular Itch Score From Baseline [ 0 hours, 12 hours ]

Show Outcome Measure 1

2. Secondary:

Ocular Comfort Score at 12 Hours [ 12 hours ]

Show Outcome Measure 2